MHRA authorises Diurnal’s CAH therapy Efmody
Congenital adrenal hyperplasia (CAH) is a rare condition caused by deficiency of adrenal enzymes
Read More
Tag: Diurnal
Diurnal seeks marketing authorisation for Chronocort in the UK
MHRA submission is based on same application filed with the EMA
Read More
Diurnal files Chronocort in the EU
If approved, the firm will be able to offer lifelong treatment for the rare condition congenital adrenal hyperplasia
Read More
EMA confirms path for Diurnal’s Chronocort despite trial failure
The company is on track to submit a Marketing Authorisation Application in the fourth quarter of 2019.
Read More
Diurnal shares plummet on trial failure
Shares in UK speciality pharma Diurnal plummeted more than 50 percent on news that a late-stage study of an experimental treatment for congenital adrenal hyperplasia (CAH) failed to meet its primary objective.
Read More
Seven therapies backed for EU approval
Seven therapies have been put forward for approval in the European Union, bringing closer new options for a range of conditions including Crohn’s disease, diabetes and cancer.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
